Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes
- 15 July 2000
- Vol. 89 (2) , 383-390
- https://doi.org/10.1002/1097-0142(20000715)89:2<383::aid-cncr25>3.0.co;2-t
Abstract
BACKGROUND The high mortality associated with ovarian carcinoma is largely a reflection of the inability to diagnose the disease at an early stage; the identification of a histologic lesion or molecular marker associated early stages of transformation would represent an important advance in understanding the natural history of this cancer. The existence of individuals with germline mutations in the ovarian and breast carcinoma susceptibility gene BRCA1 represents a unique opportunity to search for such premalignant alterations in ovarian tissues that are at unusually high risk for tumorigenesis. In this study, the authors addressed the hypothesis that pathologically normal ovaries removed from BRCA1 heterozygotes are likely to display premalignant histologic, molecular, and/or cell biologic alterations that may provide insight into early stages of ovarian tumorigenesis. METHODS Ovarian tissues from 18 BRCA1 heterozygotes and from 20 age‐matched controls were examined in a blinded fashion for histologic evidence of surface epithelial pseudostratification, epithelial inclusion cysts, deep cortical invaginations of surface epithelium, increased stromal cell activity, and surface papillomatosis. Immunohistochemical analyses for expression of BRCA1, p53, and ERBB‐2 and quantitation of cell proliferation (Ki‐67 expression) and apoptosis (TUNEL assay), were also performed on all specimens. RESULTS Although histologic alterations were observed, there was no difference in frequency between cases and controls. Analysis of BRCA1 expression revealed ubiquitous nuclear immunoreactivity in the surface epithelial cells of all ovaries. Similarly, no evidence was found of p53 overexpression in any ovarian tissue or of a difference in ERBB‐2 expression between cases and controls. Finally, no differences were observed in epithelial cell proliferation or apoptosis. CONCLUSIONS Clinically, normal ovaries from BRCA1 heterozygotes do not show evidence of premalignant alterations in histology, molecular markers, cell proliferation, or apoptosis, indicating that such changes are likely rare. Cancer 2000;89:383–90. © 2000 American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Ovarian dysplasia in prophylactic oophorectomy specimensCancer, 1999
- The Contribution of Germline BRCA1 and BRCA2 Mutations to Familial Ovarian Cancer: No Evidence for Other Ovarian Cancer–Susceptibility GenesAmerican Journal of Human Genetics, 1999
- Comparison of Prophylactic Oophorectomy Specimens From Carriers and Noncarriers of a BRCA1 or BRCA2 Gene MutationJNCI Journal of the National Cancer Institute, 1999
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesAmerican Journal of Human Genetics, 1998
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- Expression and mutational analysis of P53 in stage IB and IIA cervical cancersAmerican Journal of Obstetrics and Gynecology, 1996
- Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family hostory of ovarian cancerPublished by Elsevier ,1995
- Unusual case of Smith‐Lemli‐Opitz syndrome “type II”American Journal of Medical Genetics, 1995
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.The Journal of cell biology, 1992
- A survey of epithelial inclusions in the ovarian cortex of 470 patientsJournal of Surgical Oncology, 1976